In silico screen identifies celastrol against sarcopenia

Researchers reported this month that an in silico transcriptome-based screen identified celastrol as a candidate drug against aging-related sarcopenia, a syndrome marked by progressive loss of muscle mass and function. The study, published in the *Journal of Advanced Research*, matched gene-expression signatures across species and then tested the compound in muscle cells, mice and aged *Caenorhabditis elegans*. The authors said celastrol emerged as a top candidate because its transcriptional profile resembled the effects of exercise and muscle-specific PGC-1α activation, a pathway tied to mitochondrial biogenesis and oxidative metabolism. They wrote that the findings support celastrol as a possible “exercise mimetic,” while stressing that further validation is needed before any clinical use. ### How did the researchers look for a sarcopenia drug without starting in the lab? The study used age-stratified muscle transcriptome datasets from multiple species and compared them with gene-expression signatures linked to exercise and PGC-1α overexpression, according to the paper abstract. The team then used Connectivity Map, a database that matches disease or biological states with compounds that can reverse or mimic their transcriptional patterns, to screen for candidates. Celastrol was identified as a leading hit from that computational step. (sciencedirect.com) PGC-1α, named in the study design, is a regulator of mitochondrial biogenesis and oxidative metabolism in muscle. The authors framed their search around the idea that exercise can slow muscle aging through that pathway, but that frailty and declining mobility can limit exercise in older adults. On that basis, they looked for a compound that could reproduce part of the same molecular program. (read.qxmd.com) ### What exactly is celastrol, and why did it stand out? Celastrol is a bioactive triterpenoid derived from *Tripterygium wilfordii* Hook. F., the paper said. In the screen, it stood out because it mimicked gene signatures associated with PGC-1α overexpression or exercise intervention, according to the abstracted study description. (read.qxmd.com) The authors reported that celastrol improved myogenic differentiation and mitochondrial bioenergetic capacity in vitro and in vivo. They also linked the compound to restoration of muscle integrity and mitochondrial morphology in aged worms and to improved muscle decline measures in an accelerated-aging mouse model. Those findings are the basis for the study’s claim that celastrol may act on mitochondrial pathways relevant to sarcopenia. (read.qxmd.com) ### What did the cross-species tests show after the computer screen? The validation work extended beyond the computational screen to C2C12 myoblasts, young mice, aged *C. elegans* and D-galactose-induced accelerated-aging mice, according to the study summary. In worms, the paper reported that celastrol extended lifespan by 27.6% at 10 μM while reducing aging markers and improving muscle and mitochondrial features. (sciencedirect.com) In mouse and cell experiments, the authors said celastrol boosted myogenic differentiation and mitochondrial oxidative metabolism. The paper summary also said the in vivo work found no side effects in the tested settings, though that statement comes from preclinical models rather than human trials. (read.qxmd.com) ### Does this mean celastrol is ready as a treatment for older adults? The study does not report a human clinical trial, and the evidence described so far is preclinical. The paper’s own design centers on transcriptomic screening followed by validation in cells, worms and mouse models, which means the findings are best understood as an early-stage drug-discovery result rather than a treatment recommendation. (read.qxmd.com) Sarcopenia still lacks approved therapeutics, the authors said in the study background. Their next step, as laid out in the paper, is further laboratory validation of celastrol’s effects on muscle aging and mitochondrial dysfunction across species and models before any move toward translational development. (read.qxmd.com)